Previously, the launch-free brain interface (BCI) and the ARtechnology developer Cognixion announced that its flagship equipment Cognixion ONETM Axon had been certified by the United States Food and Drug Administration (FDA) breakthrough equipment, which would enable the company to simplify the development and certification process in accordance with the priority interactive feedback of FDA reviewers, thereby laying the groundwork for subsequent submission of regulatory documents. It is known...